Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Limited announced it will release its financial and operating results for the year ending June 30, 2025, on August 26, 2025. The announcement includes an investor webinar hosted by CEO Melinda McGrath and CFO Matt Cordingley, which will provide stakeholders with insights into the company’s performance and strategic direction. This event is significant for stakeholders as it offers a platform for understanding ACL’s financial health and future plans, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that perform a wide range of pathology tests for clients such as doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in the country, focusing on combining talented personnel and scientific leadership with innovative technologies to enhance patient care.
Average Trading Volume: 850,097
Technical Sentiment Signal: Sell
Current Market Cap: A$530.3M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.